Top 5 Fastest Growing Pharma & Biotech Companies in Europe in 2026

Europe’s pharmaceutical landscape is being shaped by a new wave of fast-growing, innovation-driven companies.

According to reporting by the Financial Times based on data from Statista, these companies are among the fastest-growing in the region, driven by strong revenue growth between 2021 and 2024.

From digital health platforms to consumer-focused therapeutics and niche biotech services, these firms reflect growing pharma trends toward specialization, direct-to-consumer (DTC) models and tech-enabled drug development.

1. Itaste Medical (Italy)

Itaste Medical specializes in the wholesale distribution of pharmaceutical products and base pharmaceutical preparations. It was founded in 2019, and in recent years, the company has experienced rapid revenue growth, transforming from a smaller operation into a multi-million Euro revenue company. In 2024, total sales were valued at €18.4 billion ($21.34 billion), having grown at a tremendous absolute growth rate (AGR) of 2,035.6% and compound annual growth rate (CAGR) of 177.4% from its 2021 earnings of €863,718 ($1 million).

Related: Top 15 Pharma & Biotech Companies to Work For in 2026, According to Forbes

2. Grow Group (UK)

Grow Group operates in the UK’s evolving health and wellness ecosystem, with a focus on scalable healthcare brands and product distribution centered on cannabis-based medicines for patients. Founded in 2017 at the height of the cannabis boom, the company’s growth reflects rising demand for consumer-facing pharmaceutical and wellness solutions, particularly those delivered through e-commerce and DTC platforms. Its expansion strategy appears to rely on brand-building and portfolio diversification rather than traditional drug development. It experienced significant growth between 2021 and 2024, with sales increasing from €6.12 billion ($7.09 billion) to €30.49 billion ($35.34 billion) at an AGR of 391.8% and a CAGR of 70.1%.

3. Labtoo (France)

Labtoo is focused on early-stage drug development through a crowdsourced R&D model. The company is focused on scientific services for sourcing biological samples and experimental models. It offers comprehensive scientific and regulatory support along with project management. By connecting pharmaceutical companies with a global network of research laboratories, Labtoo aims to accelerate experimentation and reduce costs. Its growth reflects increasing demand for outsourced and flexible drug discovery services, particularly among smaller biotech firms looking to scale efficiently. In 2021, Labtoo sales were  €530,773 million ($615,192 million) and grew at an AGR of 269.6% and CAGR of 54.6% to €1.96 billion ($2.27 billion) in 2024. 

4. Farmed (Italy)

Farmed operates in the distribution and commercialization of pharmaceutical and health products, with a focus on scaling access across Italy and beyond. While not a traditional drug developer, Farmed plays a key role in ensuring product availability in a fragmented European market. The company says it chooses drugs, medical devices and cosmetics throughout Europe, monitoring the entire distribution chain to guarantee Italian customers quality and safety of products in compliance with GDP standards. The company exclusively sources products from authorized and certified European wholesalers. Farmed’s growth reflects the increasing importance of efficient supply chains and digital ordering systems in pharma distribution. Over a three-year period, company sales grew from €9.16 billion ($10.62 billion) to €24.79 billion ($28.74 billion) at an AGR of 170.7% and a CAGR of 39.4%.

5. Exystat (France)

Exystat is a contract research organization (CRO) that operates at the intersection of data, analytics and healthcare. It offers pharmaceutical and biotech companies with services in electronic data capture (EDC), data management, statistics and methodology to support all phases of clinical studies. Founded in 2013, Exystat’s revenue increased from €1.71 billion ($13.57 billion) in 2021 to €3.04 billion ($3.52 billion) in 2024 at an AGR of 77.7% and a CAGR of 21.1%.